Jay Bradner, M.D.Ovjeren akaunt

@jaybradner

Physician-scientist & President leading NIBR (), focused on definitive therapies for life-threatening diseases . Tweets = my own.

Cambridge, MA
Vrijeme pridruživanja: rujan 2011.

Tweetovi

Blokirali ste korisnika/cu @jaybradner

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @jaybradner

  1. Thanks for everything you do in and , . Read more in her wonderful Q&A with questions submitted by readers

    Poništi
  2. The high mutational burden of smoking in non-malignant lung airway cells. Terrifying

    Poništi
  3. An exciting update on our Cancer Cell Line Encyclopedia: Quantified proteome profiles for 375 cell lines in .

    Poništi
  4. CAN’T. STOP. ROTATING. The human SWI/SNF complex at 3.7 A resolution, bound to a nucleosome, complements of Yanhui Xu and .

    Poništi
  5. proslijedio/la je Tweet

    “This is what happens when a structural biologist starts hanging around with a bunch of kinase-obsessed genetic screeners and cell signaling geeks!”

    Poništi
  6. Phil’s mission is the NIBR mission – to innovate strategically so that we can fulfill our promise to help bring new medicines to patients efficiently

    Poništi
  7. That’s an old worm.

    Poništi
  8. A joy to be back in Mission Bay for the - Innovations in Regulatory Science Summit, comparing notes on the path to patients for new therapeutic modalities.

    Poništi
  9. Ambition is not something we shy away from in our journey to bring innovative medicines to patients. 2020 will be no different—here’s how:

    Poništi
  10. Touching story that’s moving as a researcher & a parent. Thank you for sharing the story behind the

    Poništi
  11. I’m interested to hear what others in the scientific community think will be the biggest stories of 2020. shares their list here:

    Poništi
  12. Helpful discussion on the importance of permeability in targeted protein degradation, based on recent work out of UNC. blog in :

    Poništi
  13. So cool to see Lynn Hershman Leeson’s “Anti-Bodies” listed as one of the “Best Art Books of 2019” in . Fun fact: the LYNNHERSHMAN antibody grew out of an art-science collaboration w/ Thomas Huber at NIBR-Basel.

    Poništi
  14. Thank you for your generous consideration highlighting ' accomplishments in 2019. Well done to all those who contributed to getting much needed drugs to the finish line!

    Poništi
  15. “Investment in open can promote resilient workflows and reinforce a culture of inclusion, trust and innovation.” More in Nature:

    Poništi
  16. Poništi
  17. Fun on recent NIBR work investigating DCAF15’s potential in . Includes a brief explainer re: molecular glue degraders, for the curious.

    Poništi
  18. The latest research on our CDK4/6 inhibitor in metastatic breast cancer, discovered , is now available in . Study shows targeted therapy could potentially help some women with a particular type of aggressive live longer

    Poništi
  19. It was a pleasure to talk about next-gen cancer therapeutics last week with the folks . Thanks for the invite! 🍕

    Poništi
  20. Encouraging Phase 1 performance of our home grown, allosteric ABL in today's . Allostery, oncogenes and overcoming resistance, all specialities of the house.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·